This post significantly adds to the conversation in Effective Altruism about how pain is distributed. As explained in the review of Log Scales, understanding that intense pain follows a long-tail distributions significantly changes the effectiveness landscape for possible altruistic interventions. In particular, this analysis shows that finding the top 5% of people who suffer the most in a given medical condition and treating them as the priority will allow us to target a very large fraction of the total pain such a condition generates. In the case of cluster headaches, the distribution is extremely skewed: 5% of sufferers experience over 50% of all cluster headaches.
More so, the survey also showed that the leading cause for why sufferers don’t use tryptamines to treat their condition is the difficulty of acquiring them. Thus, changing the legal landscape via e.g. providing programs for the easy access to tryptamines to sufferers of migraines and cluster headaches might be a very cost-effective way of massively reducing suffering throughout the world.
Zooming out, perhaps the significance of this goes beyond cluster headaches in particular: it perhaps hints at a more significant paradigmatic change for analyzing the cost-effectiveness of interventions.
This post significantly adds to the conversation in Effective Altruism about how pain is distributed. As explained in the review of Log Scales, understanding that intense pain follows a long-tail distributions significantly changes the effectiveness landscape for possible altruistic interventions. In particular, this analysis shows that finding the top 5% of people who suffer the most in a given medical condition and treating them as the priority will allow us to target a very large fraction of the total pain such a condition generates. In the case of cluster headaches, the distribution is extremely skewed: 5% of sufferers experience over 50% of all cluster headaches.
More so, the survey also showed that the leading cause for why sufferers don’t use tryptamines to treat their condition is the difficulty of acquiring them. Thus, changing the legal landscape via e.g. providing programs for the easy access to tryptamines to sufferers of migraines and cluster headaches might be a very cost-effective way of massively reducing suffering throughout the world.
Zooming out, perhaps the significance of this goes beyond cluster headaches in particular: it perhaps hints at a more significant paradigmatic change for analyzing the cost-effectiveness of interventions.